Results 141 to 150 of about 10,848 (199)

Retrospective study of treatment effectiveness and remission predictors of obinutuzumab in primary membranous nephropathy. [PDF]

BMC Nephrol
Jiang Z, Zhou S, Bao W, Wang S, Wang Y, Zheng D.   +5 more
europepmc   +1 more source

Clinical effect of obinutuzumab in the treatment of idiopathic membranous nephropathy. [PDF]

Am J Transl Res
Ning S, Zhang Q, Shang Z, Liu H.
europepmc   +1 more source

Case Report: Zanubrutinib for refractory immune thrombotic thrombocytopenic purpura. [PDF]

Front Immunol
De Angelis AD, Schnegg-Kaufmann A, Moutzouri E, Jalowiec KA, Ratknic M, Kremer Hovinga JA, Chanias I.   +6 more
europepmc   +1 more source

Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries. [PDF]

Future Oncol
Patel H, Huynh L, Squires P, Prescott J, Ryland K, Catillon M, Guo T, Tamakloe K, Liu S, Duh MS, Raut M, Portell CA.   +11 more
europepmc   +1 more source

The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma. [PDF]

Blood Cancer J
Xu J, Li J, Ren Y, Cheng L, Cheng Z, Zhuang J, Ke Y, Gu S, Zhang Y, Chen F, Gao R, Li P, Xiong Y, Liu P.   +13 more
europepmc   +1 more source

B- and plasma cell-targeting therapies for podocytopathies: state of the art and the New Gaslini protocol. [PDF]

Clin Kidney J
Cravedi P, Spennacchio A, Bigatti C, Kajana X, Caridi G, Angeletti A.   +5 more
europepmc   +1 more source

Response to the Letter to the Editor Entitled "Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy". [PDF]

Kidney Int Rep
Giri K, Glassock RJ, Fervenza FC.
europepmc   +1 more source

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. [PDF]

Cancer Med
Liao PW, Ko BS, Su YC, Chao WT, Teng CJ.
europepmc   +1 more source

Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy. [PDF]

Kidney Int Rep
Ruggenenti P, Trillini M, Podestà MA, Remuzzi G.   +3 more
europepmc   +1 more source

Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial. [PDF]

Neurol Ther
Wu L, Wei M, Gao F, Zhang H, Wang J, Xiang F, Gao S, Liu R, Yin J, Guo Y, Liu X, Liang J, Liu S, Li F, Huang D.   +14 more
europepmc   +1 more source